Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

2(66.7%)

Phase 3

1(33.3%)

3Total

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT01733082Recruiting

The Mycophenolate Pregnancy Registry

Role: collaborator

NCT05405725Phase 3Completed

A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

Role: collaborator

NCT05245669Phase 1Completed

Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers

Role: collaborator

NCT06678113Phase 1Recruiting

Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients With Invasive Fungal Infection

Role: collaborator

All 4 trials loaded